Comment on "Reactogenicity Study of mRNA COVID-19 Vaccine"

Abstract

Dear Editor, we would like to share ideas on the publication “Reactogenicity Study of mRNA Vaccines Against COVID-19.” Inglés Torruella et al. compare the reactogenicity of two types of mRNA vaccines against COVID-19, Commirnaty® (Pfizer) and Spikevax® (Moderna), in a healthcare population. According to Inglés Torruella et al., the greater reactogenicity and its consequences for the first and second doses of the Spikevax® vaccine compared to Comirnaty®, and for the second dose compared to the first dose of both vaccines, provides useful knowledge for planning COVID-19 vaccination campaigns in healthcare settings.

A variety of factors need to be looked at in order to fully understand the results. It is impossible to draw a relationship between asymptomatic COVID-19 and the lack of symptoms without the required laboratory investigations. Without extensive laboratory testing, asymptomatic COVID-19 and the lack of clinical symptoms could be incorrectly diagnosed. A silent COVID-19 must be ruled out if neither the most recent clinical signals nor the most recent clinical markers are present. Additionally, genetic variations appear to affect how certain individuals' immune systems react to COVID-19. Before the findings can be verified, more clinical study will be needed.